- /
- Supported exchanges
- / US
- / CRBU.NASDAQ
Caribou Biosciences Inc (CRBU NASDAQ) stock market data APIs
Caribou Biosciences Inc Financial Data Overview
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Caribou Biosciences Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Caribou Biosciences Inc data using free add-ons & libraries
Get Caribou Biosciences Inc Fundamental Data
Caribou Biosciences Inc Fundamental data includes:
- Net Revenue: 9 295 K
- EBITDA: -135 692 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Caribou Biosciences Inc News
New
Spotlight On Promising Penny Stocks In January 2026
Major stock indexes in the United States are showing mixed performance, with the Dow Jones Industrial Average rising while data-storage shares weigh on the Nasdaq. For investors willing to explore bey...
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], d...
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting B...
Caribou Bioscience GAAP EPS of -$0.30 beats by $0.07, revenue of $2.2M misses by $0.07M
* Caribou Bioscience press release [https://seekingalpha.com/pr/20305067-caribou-biosciences-reports-third-quarter-2025-financial-results-and-provides-business-update] (CRBU [https://seekingalpha.co...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.